85 related articles for article (PubMed ID: 11559997)
1. [Use of WOBE-MUGOS E for prevention and correction of experimental doxorubicin side-effects].
Todor IN; Solianik GI; Iurchenko OV; Shpilevaia SI; Luk'ianova NIu; Trindiak VP; Kunskaia LN; Ponomareva OV; Terzov AI; Kulik GI; Chekhun VF
Lik Sprava; 2001; (3):116-21. PubMed ID: 11559997
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Wobe-Mugos E for reduction of oral mucositis after radiotherapy : results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter study.
Dörr W; Herrmann T;
Strahlenther Onkol; 2007 Mar; 183(3):121-7. PubMed ID: 17340069
[TBL] [Abstract][Full Text] [Related]
3. Micronuclei evaluation of reduction in neoadjuvant chemotherapy related acute toxicity in locally advanced lung cancer: an indian experience.
Bahl A; Chander S; Julka PK; Rath GK; Sharma DN; Kumar A; Nair O
J Assoc Physicians India; 2006 Mar; 54():191-5. PubMed ID: 16800343
[TBL] [Abstract][Full Text] [Related]
4. [The effect of the preparation Wobe-Mugos E on the functional and biochemical status of the kidneys in the polyuric stage of sublimate-induced nephropathy].
Rohovyĭ IuIe; Myslyts'kyĭ VF; Filipova LO; Shapovalov VP; Mahalias MV; Maĭkan RI; Chortyk IuB
Fiziol Zh (1994); 2000; 46(3):51-6. PubMed ID: 11059387
[TBL] [Abstract][Full Text] [Related]
5. [Systemic enzyme therapy with the preparation Wobe-Mugos E in the combined treatment of lung cancer patients].
Smolanka II
Lik Sprava; 2000; (5):121-3. PubMed ID: 11031472
[TBL] [Abstract][Full Text] [Related]
6. [Wobe-Mugos: a proteolytic enzyme combination for tumor therapy. Documentation No. 7].
Schweiz Rundsch Med Prax; 1987 Dec; 76(51):1430-2. PubMed ID: 3326110
[No Abstract] [Full Text] [Related]
7. [Effect of the preparation Wobe-Mugos E on parameters of the antioxidant defence system and morphofunctional erythrocyte status in patients with chronic obstructive bronchitis].
Kolomoiets' MIu; Kovalenko SV; Todoriko LD
Lik Sprava; 2000 Sep; (6):100-4. PubMed ID: 11478274
[TBL] [Abstract][Full Text] [Related]
8. [Effects of proteolytic enzyme therapy with Wobe Mugos against chemotherapy-induced toxicity in breast cancer patients - results of a pilot study].
Petru E; Stranz B; Petru C
Wien Med Wochenschr; 2010 Nov; 160(19-20):513-6. PubMed ID: 20972712
[TBL] [Abstract][Full Text] [Related]
9. Polyenzyme preparation Wobe-Mugos inhibits growth of solid tumors and development of experimental metastases in mice.
Wald M; Závadová E; Poucková P; Zadinová M; Boubelik M
Life Sci; 1998; 62(3):PL43-8. PubMed ID: 9488106
[TBL] [Abstract][Full Text] [Related]
10. Double-blind pilot-study on the efficacy of enzyme therapy in advanced colorectal cancer.
Popiela T; Kulig J; Kłek S; Wachol D; Bock PR; Hanisch J
Przegl Lek; 2000; 57 Suppl 5():142. PubMed ID: 11202281
[TBL] [Abstract][Full Text] [Related]
11. The role of Wobe-Mugos in reducing acute sequele of radiation in head and neck cancers--a clinical phase-III randomized trial.
Kaul R; Mishra BK; Sutradar P; Choudhary V; Gujral MS
Indian J Cancer; 1999; 36(2-4):141-8. PubMed ID: 10921218
[TBL] [Abstract][Full Text] [Related]
12. Influence of a complementary treatment with oral enzymes on patients with colorectal cancers--an epidemiological retrolective cohort study.
Popiela T; Kulig J; Hanisch J; Bock PR
Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S55-63. PubMed ID: 11561874
[TBL] [Abstract][Full Text] [Related]
13. [Application of systemic enzyme therapy in combined treatment of patients with pulmonary cancer and malignant thymoma].
Hanul VL; Smolanka II; Ponomar'ova OV
Klin Khir; 2000 Jun; (6):17-9. PubMed ID: 11288269
[TBL] [Abstract][Full Text] [Related]
14. [The use of enzymes in treating patients with malignant lymphoma with a large tumor mass].
Gubareva AA
Lik Sprava; 1998 Aug; (6):141-3. PubMed ID: 9844901
[TBL] [Abstract][Full Text] [Related]
15. [Systemic enzymotherapy as a method of prophylaxis of postradiation complications in oncological patients].
Hubarieva HO; Kindzel's'kyĭ LP; Ponomar'ova OV; Udatova TV; Shpil'ova SI; Smolanka II; Korovin SI; Ivankin VS
Lik Sprava; 2000; (7-8):94-100. PubMed ID: 16786662
[TBL] [Abstract][Full Text] [Related]
16. [Modification of liver parameters by adjuvant administration of proteolytic enzymes following chemotherapy in patients with ovarian carcinoma].
Lahousen M
Wien Med Wochenschr; 1995; 145(24):663-8. PubMed ID: 8585220
[TBL] [Abstract][Full Text] [Related]
17. The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat.
Rahimi Balaei M; Momeny M; Babaeikelishomi R; Ejtemaei Mehr S; Tavangar SM; Dehpour AR
Eur J Pharmacol; 2010 Sep; 641(2-3):193-8. PubMed ID: 20534381
[TBL] [Abstract][Full Text] [Related]
18. [Action of doxorubicin and a doxorubicin-heparin complex on the growth and metastasis of experimental tumors and the hemostatic system indices].
Kalishevskaia TM; Bashkov GV; Repina NIu; Shpilevaia MV; Modina LS
Eksp Onkol; 1988; 10(4):59-62. PubMed ID: 3181077
[TBL] [Abstract][Full Text] [Related]
19. [Phospholipid and cholesterol levels in the tumor cell plasma membranes with different sensitivity to doxorubicin].
Chekhun VF; Tryndiak VP; Todor IM; Mykhaĭlenko VM; Kondrychyn IH; Dovbeshko HI; Repnyts'ka OP; Kulyk HI
Ukr Biokhim Zh (1999); 2003; 75(4):120-5. PubMed ID: 14681985
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective effects of nicorandil, a mitochondrial potassium channel opener against doxorubicin-induced cardiotoxicity in rats.
Abdel-Raheem IT; Taye A; Abouzied MM
Basic Clin Pharmacol Toxicol; 2013 Sep; 113(3):158-66. PubMed ID: 23621757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
